PADAGIS LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris

Phase 3

Completed

Conditions: Acne

Interventions: Drug: Adapalene and Benzoyl Peroxide Gel
Drug: Adapalene and Benzoyl Peroxide Gel (Reference)
Drug: Placebo gel

First Posted Date: 2015-08-17

Last Posted Date: 2021-11-02

Lead Sponsor: Padagis LLC

Target Recruit Count: 903

Registration Number: NCT02525549

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

Phase 3

Completed

Conditions: Acne

Interventions: Drug: Clindamycin and Benzoyl Peroxide Gel (combination)
Drug: Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)
Drug: Placebo gel (combination)

First Posted Date: 2015-08-04

Last Posted Date: 2021-11-08

Lead Sponsor: Padagis LLC

Target Recruit Count: 890

Registration Number: NCT02515305

Locations: 🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States

To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Ingenol Mebutate (Perrigo)
Drug: Ingenol Mebutate (Reference)
Drug: Placebo gel

First Posted Date: 2015-06-02

Last Posted Date: 2021-11-02

Lead Sponsor: Padagis LLC

Target Recruit Count: 469

Registration Number: NCT02459795

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: Brimonidine Topical Gel, 0.33 percent (Perrigo)
Drug: Brimonidine Topical Gel, 0.33 percent (Reference)
Drug: Placebo gel

First Posted Date: 2015-03-11

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 552

Registration Number: NCT02385240

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Ingenol Mebutate (Reference)
Drug: Placebo gel
Drug: Ingenol Mebutate (Perrigo)

First Posted Date: 2015-03-11

Last Posted Date: 2021-11-02

Lead Sponsor: Padagis LLC

Target Recruit Count: 519

Registration Number: NCT02385318

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

Phase 3

Completed

Conditions: Herpes Labialis

Interventions: Drug: Acyclovir 5 percent (Perrigo)
Drug: Placebo cream
Drug: Acyclovir 5 percent (Reference)

First Posted Date: 2014-10-16

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 4076

Registration Number: NCT02265913

Locations: 🇺🇸
Quality Clinical Research Inc, Omaha, Nebraska, United States

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
Drug: Placebo nasal spray

First Posted Date: 2014-09-03

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 951

Registration Number: NCT02230696

Locations: 🇺🇸
Chesapeake Clinical Research, Inc., Baltimore, Maryland, United States
🇺🇸
Clinical Research Institute, Inc., Minneapolis, Minnesota, United States
🇺🇸
Clinical Research Institute LLC, Minneapolis, Minnesota, United States

and more 26 locations

A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris

Phase 3

Completed

Conditions: Acne

Interventions: Drug: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%
Drug: Acanya Gel
Drug: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product

First Posted Date: 2013-02-22

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 1180

Registration Number: NCT01796665

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Placebo nasal spray
Drug: Nasonex Nasal Spray
Drug: Mometasone furoate

First Posted Date: 2012-08-28

Last Posted Date: 2021-10-22

Lead Sponsor: Padagis LLC

Target Recruit Count: 1220

Registration Number: NCT01673659

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Entocort

First Posted Date: 2011-10-18

Last Posted Date: 2022-01-06

Lead Sponsor: Padagis LLC

Target Recruit Count: 55

Registration Number: NCT01453946

Locations: 🇵🇱
Research Site, Łódź, Poland

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy